EquitySector - HealthcareVery High Risk
Regular
NAV (17-Apr-25)
Returns (Since Inception)
Fund Size
₹10 Cr
Expense Ratio
0.19%
ISIN
INF740KA1UF4
Minimum SIP
-
Exit Load
-
Inception Date
01 Feb 2024
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+15.81%
+17.55% (Cat Avg.)
Since Inception
+17.22%
— (Cat Avg.)
Equity | ₹9.76 Cr | 99.95% |
Others | ₹0.01 Cr | 0.05% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹2.01 Cr | 20.63% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹0.88 Cr | 8.99% |
Cipla Ltd | Equity | ₹0.87 Cr | 8.95% |
Divi's Laboratories Ltd | Equity | ₹0.79 Cr | 8.08% |
Dr Reddy's Laboratories Ltd | Equity | ₹0.75 Cr | 7.70% |
Apollo Hospitals Enterprise Ltd | Equity | ₹0.72 Cr | 7.37% |
Lupin Ltd | Equity | ₹0.53 Cr | 5.40% |
Fortis Healthcare Ltd | Equity | ₹0.39 Cr | 3.98% |
Torrent Pharmaceuticals Ltd | Equity | ₹0.36 Cr | 3.72% |
Aurobindo Pharma Ltd | Equity | ₹0.35 Cr | 3.58% |
Mankind Pharma Ltd | Equity | ₹0.29 Cr | 2.99% |
Alkem Laboratories Ltd | Equity | ₹0.28 Cr | 2.86% |
Laurus Labs Ltd | Equity | ₹0.26 Cr | 2.65% |
Glenmark Pharmaceuticals Ltd | Equity | ₹0.25 Cr | 2.56% |
Zydus Lifesciences Ltd | Equity | ₹0.24 Cr | 2.44% |
Ipca Laboratories Ltd | Equity | ₹0.22 Cr | 2.30% |
Abbott India Ltd | Equity | ₹0.17 Cr | 1.76% |
Biocon Ltd | Equity | ₹0.17 Cr | 1.70% |
Syngene International Ltd | Equity | ₹0.15 Cr | 1.51% |
Granules India Ltd | Equity | ₹0.08 Cr | 0.78% |
Treps / Reverse Repo Investments | Cash - Repurchase Agreement | ₹0 Cr | 0.04% |
Net Receivables/Payables | Cash | ₹0 Cr | 0.02% |
Large Cap Stocks
51.51%
Mid Cap Stocks
45.01%
Small Cap Stocks
3.42%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹9.76 Cr | 99.95% |
Standard Deviation
This fund
--
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Since February 2024
Since February 2024
ISIN INF740KA1UF4 | Expense Ratio 0.19% | Exit Load - | Fund Size ₹10 Cr | Age 1 year 2 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark Nifty Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
Total AUM
₹1,80,251 Cr
Address
West Wing, 11th Floor, Mumbai, 400021
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Regular
NAV (17-Apr-25)
Returns (Since Inception)
Fund Size
₹10 Cr
Expense Ratio
0.19%
ISIN
INF740KA1UF4
Minimum SIP
-
Exit Load
-
Inception Date
01 Feb 2024
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+15.81%
+17.55% (Cat Avg.)
Since Inception
+17.22%
— (Cat Avg.)
Equity | ₹9.76 Cr | 99.95% |
Others | ₹0.01 Cr | 0.05% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹2.01 Cr | 20.63% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹0.88 Cr | 8.99% |
Cipla Ltd | Equity | ₹0.87 Cr | 8.95% |
Divi's Laboratories Ltd | Equity | ₹0.79 Cr | 8.08% |
Dr Reddy's Laboratories Ltd | Equity | ₹0.75 Cr | 7.70% |
Apollo Hospitals Enterprise Ltd | Equity | ₹0.72 Cr | 7.37% |
Lupin Ltd | Equity | ₹0.53 Cr | 5.40% |
Fortis Healthcare Ltd | Equity | ₹0.39 Cr | 3.98% |
Torrent Pharmaceuticals Ltd | Equity | ₹0.36 Cr | 3.72% |
Aurobindo Pharma Ltd | Equity | ₹0.35 Cr | 3.58% |
Mankind Pharma Ltd | Equity | ₹0.29 Cr | 2.99% |
Alkem Laboratories Ltd | Equity | ₹0.28 Cr | 2.86% |
Laurus Labs Ltd | Equity | ₹0.26 Cr | 2.65% |
Glenmark Pharmaceuticals Ltd | Equity | ₹0.25 Cr | 2.56% |
Zydus Lifesciences Ltd | Equity | ₹0.24 Cr | 2.44% |
Ipca Laboratories Ltd | Equity | ₹0.22 Cr | 2.30% |
Abbott India Ltd | Equity | ₹0.17 Cr | 1.76% |
Biocon Ltd | Equity | ₹0.17 Cr | 1.70% |
Syngene International Ltd | Equity | ₹0.15 Cr | 1.51% |
Granules India Ltd | Equity | ₹0.08 Cr | 0.78% |
Treps / Reverse Repo Investments | Cash - Repurchase Agreement | ₹0 Cr | 0.04% |
Net Receivables/Payables | Cash | ₹0 Cr | 0.02% |
Large Cap Stocks
51.51%
Mid Cap Stocks
45.01%
Small Cap Stocks
3.42%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹9.76 Cr | 99.95% |
Standard Deviation
This fund
--
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Since February 2024
Since February 2024
ISIN INF740KA1UF4 | Expense Ratio 0.19% | Exit Load - | Fund Size ₹10 Cr | Age 1 year 2 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark Nifty Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
Total AUM
₹1,80,251 Cr
Address
West Wing, 11th Floor, Mumbai, 400021
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments